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Abstract
Background: Incidental and secondary findings (IFs and SFs) are subject to ongoing discussion as potential
consequences of clinical exome sequencing (ES). International policy documents vary on the reporting of these
findings. Discussion points include the practice of unintentionally identified IFs versus deliberately pursued SFs,
patient opt-out possibilities and the spectrum of reportable findings. The heterogeneity of advice permits a non-
standardised disclosure but research is lacking on actual reporting practices. Therefore, this study assessed
national reporting practices for IFs and SFs in clinical ES and the underlying professional perspectives.
Methods: A qualitative focus group study has been undertaken, including professionals from Belgian centres for
medical genetics (CMGs). Data were analysed thematically.
Results: All Belgian CMGs participated in this study. Data analysis resulted in six main themes, including one
regarding the reporting criteria used for IFs. All CMGs currently use ES-based panel testing. They have limited
experience with IFs in clinical ES and are cautious about the pursuit of SFs. Two main reporting criteria for IFs
were referred to by all CMGs: the clinical significance of the IF (including pathogenicity and medical actionability) and
patient-related factors (including the patient’s preference to know and patient characteristics). The consensus over the
importance of these criteria contrasted with their challenging interpretation and application. Points of concern
included IFs’ pathogenicity in non-symptomatic persons, IFs concerning variants of uncertain significance, the
requirement and definition of medical actionability and patient opt-out possibilities. Finally, reporting decisions
were guided by the interaction between the clinical significance of the IF and patient characteristics. This interaction
questions the possible disclosure of findings with context-dependent and personal utility, such as IFs concerning a
carrier status. To evaluate the IF’s final relevance, a professional and case-by-case deliberation was considered essential.
Conclusions: The challenging application of reporting criteria for IFs results in diversified practices and policy
perspectives within Belgian CMGs. This echoes international concerns and may have consequences for effective policy
recommendations.
Keywords: Incidental findings, Secondary findings, Clinical exome sequencing, Disclosure, Professional practice, Focus
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Background
Incidental findings (IFs) and secondary findings (SFs),
which are variants in known disease genes unrelated to
the diagnostic indication, are subject to ongoing discussion
as potential consequences of clinical exome sequencing
(ES) [1–3]. Since ES simultaneously covers all coding
regions of a patient’s genome, results unrelated to the diag-
nostic question can be found unintentionally, as IFs, or
deliberately pursued, as SFs [2–5]. As ES is increasingly im-
plemented for the diagnosis of monogenic diseases, various
policy documents have been published regarding IFs and
SFs in the US, Europe and Canada [1–3, 5–8]. However,
these documents differ on fundamental issues and none of
them is accepted as the general standard. Issues regarding
(i) a practice of unintentional IFs versus actively pursued
SFs, (ii) patient opt-out possibilities and (iii) the spectrum
of reportable findings remain unresolved [9–11].
Firstly, the American College of Medical Genetics and
Genomics (ACMG) has published highly influential rec-
ommendations which advocate the routine analysis of an
additional panel of 59 genes and the reporting of all
(likely) pathogenic variants when performing clinical ES
[2, 3]. Pathogenic (class 5) and likely pathogenic (class 4)
variants can provide adequate grounds for altering a pa-
tient’s surveillance or treatment [12]. Class 3 variants of
uncertain significance (VUS), however, should not be
considered as sufficient grounds for clinical decision-
making [12]. Even though VUS might be reported when
possibly relevant to the diagnostic question, their report-
ing is not advised when identified as IFs [3, 4, 7, 8]. Ac-
cording to the ACMG, screening for (likely) pathogenic
variants in the diagnostically unrelated gene panel should
occur in every case of clinical exome and genome sequen-
cing, as a realisation of the professional duty to avoid
harm [2, 3, 10, 13]. However, this opportunistic screening
has been criticised and the American Presidential
Commission for the Study of Bioethical Issues (Bioethics
Commission) notes how it might entail additional health
risks, overwhelm patients with (ambivalent) information
and stimulate a trend of medicalisation [5]. Therefore,
the Bioethics Commission, and also EuroGentest, the
European Society of Human Genetics (ESHG) and the
Canadian College of Medical Geneticists (CCMG), are
more cautious in their guidelines about reporting SFs
and IFs [1, 5, 7, 8]. They advocate a strictly necessary
and proportional application of ES and, if possible,
(exome or genome-based) targeted panel testing, which
only analyses a subset of known disease-associated genes
and hence minimises the possibility of diagnostically unre-
lated IFs [1, 4, 7].
Secondly, the ACMG claims a patient’s right to opt out
of deliberately pursued SFs [13]. Taking into account all
other international policy documents’ advice of targeted
testing and their restraint towards SFs, wide agreement on
this opt-out possibility might be assumed [1, 7, 8]. Inter-
national statements are more vague, however, about opting
out of unintentional IFs. The Bioethics Commission, ESHG
and Public Health Genetics (PHG) Foundation recommend
that professionals should make a “prudent professional
judgement” [5] concerning their fiduciary duty when a pa-
tient wants to opt out of an IF that is relevant, serious, and
medically actionable (i.e. enabling surveillance and prevent-
ive and/or therapeutic interventions) [1, 3, 5, 14]. This way,
a patient’s right not to know might be overruled by a pro-
fessional’s presumed duty to avoid harm [3]. Recently pub-
lished points to consider for laboratories, however, as well
as the Canadian geneticists’ position statement, strongly ad-
vocate respect for a patient’s choice not to know IFs [6, 8].
Thirdly, the specific spectrum of genes or conditions
that should be considered as reportable IFs or SFs, as
well as the underlying reporting criteria, are strongly de-
bated [15, 16]. Lists of conditions and associated genes
(including the ACMG gene list) have been challenged by
the critique that variants might be classified differently
or might be less penetrant and expressive in asymptom-
atic persons [15]. Hence the identification of IFs or SFs
as predictive disease risks might be doubted [17]. Finally,
the possibility of medical actionability has been stressed
as an important criterion for reportable IFs and SFs in
various recommendations [1–3, 5]. Even though a semi-
quantitative metric has been developed as an attempt to
assess medical actionability objectively, this criterion has
been criticised [10, 18]. On the one hand, the mere avail-
ability of a medical intervention does not guarantee its
effectiveness, and many interventions for conditions on
the ACMG list are not supported in terms of their ef-
fectiveness by clinical trials or professional guidelines
[14]. On the other hand, it has been suggested that the
definition of medical actionability is too narrow and
should also include reproductive choices or should be
complemented by the criterion of personal utility (i.e. a
personal interest or benefit that goes beyond improved
healthcare outcomes) [15, 19].
Recently, the persistent lack of accord among policy
documents has been exemplified in an international com-
parison of consent forms used for large gene panels, ex-
ome or genome sequencing. About half of the studied
forms did not indicate their policy on reporting IFs or SFs
and many used undefined terms (leaving the reference to
IFs and/or SFs and corresponding reporting practices un-
clear) [20]. Moreover, the spectrum of reportable IFs and
SFs (if specified) as well as the options to opt in for or opt
out of (specific categories of) findings widely varied [20].
The diverse character of recommendations and con-
sent forms and their inclusion of contested terms and
criteria permits a non-standardised practice regarding
IFs and SFs. However, only a limited amount of research
has investigated the actual uptake of policy guidelines
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regarding IFs and SFs and has focussed on current
reporting practices in a context of clinical ES. A US-
based survey identified diverse practices regarding the
spectrum of reportable IFs and SFs (which considerably
exceeded the ACMG list) and different opt-in and opt-
out possibilities [21]. Outside the US, two studies, each
including laboratories from various countries, have
analogously reported a variety in reported IFs [22, 23].
This study aims to further assess the actual practice
regarding IFs and SFs in clinical ES, as well as to investi-
gate the underlying professional perspectives. This re-
search will also indicate which elements of international
policy documents have been incorporated in practice as
being most relevant or feasible and which elements
demand further consideration or adjustment for efficient
and successful policymaking.
Methods
Recruitment and data collection
To achieve an in-depth understanding of the practice
and policy regarding IFs and SFs, a qualitative study was
set up in Belgian centres for medical genetics (CMG).
Belgium has eight CMGs: three in the Flemish Region,
two in the Walloon Region and three in the Brussels-
Capital Region. Since the aim was not to find out
individual or role-specific views but the integrated
perspective of each CMG, and to stimulate open conver-
sation and interaction between colleagues, one focus
group in every CMG was considered to be most appro-
priate [24]. A purposive sampling approach was used to
recruit a multi-disciplinary and representative group of
participants in every CMG, including both clinical and
clinical laboratory geneticists and possibly other profes-
sionals. CMGs were informed about our study and its
procedure by a presentation at the Belgian College of
Medical Genetics (a federal body for quality of health-
care in medical genetics). Subsequently, a contact (usually
the head of department) at each CMG was approached by
email or telephone to request participation. If the contact
agreed, they suggested a time which suited most of the
CMG’s professionals.
All focus groups were conducted in a room at the
CMG or associated hospital between November 2016
and December 2017, and lasted between 67 and 117
min. All focus groups were moderated by the first author
and an observer was present and took field notes in
seven out of eight focus groups. Focus groups were
moderated in Dutch or English and participants could
choose to speak Dutch, French or English.
A semi-structured interview guide, created after a thor-
ough literature review, was evaluated by a multidisciplin-
ary team of an ethicist (HM), geneticist (EDB) and
philosopher (ID) and was used for all focus groups. Open-
ended questions and probes to stimulate discussion were
used (Table 1). Terminologically, “IF” was used to refer to
unintentionally identified, diagnostically unrelated results.
“SF” was used to refer to deliberately pursued, diagnostic-
ally unrelated findings. The study’s specific focus on IFs
and SFs in clinical ES for monogenic diseases, excluding
preconception, prenatal, screening and research contexts,
was emphasised at the outset of every focus group.
Data analysis
Focus groups were audio-recorded and transcribed ver-
batim and data are saved until completion of the full
research project on a password-protected server. Data
were analysed thematically, with an inductive approach
and unrestricted by theoretical concepts. The analysis
consisted of the consecutive stages of data immersion,
code generation, theme identification, theme revision,
theme definitions and production of the final report, as
described by Braun and Clarke [25]. All data were coded
by MS, and TM independently coded a substantial sub-
set of the data. Analysis was an iterative and ongoing
process during data collection. Text units could be
included in more than one code and/or theme and the
analysis was supported by use of a software program for
qualitative data analysis (NVivo12). During analysis, ideas
and reflections were stored as memos. An extensive pro-
cedure was developed to ensure the trustworthiness and
credibility of the data collection, analysis and report. The
procedure combined peer debriefing and a systematic
audit trail, and covered both the process and the product
of the analysis [26]. Following TM’s secondary analysis of
a data subset, the transcripts and initial code schemes
were reviewed and theme names, definitions and struc-
tures were thoroughly discussed by MS and TM. Prelim-
inary thematic structures and draft reports were discussed
Table 1 Examples of interview questions
How do you describe an IF in a clinical context in your CMG, apart from
following guidelines? What terminology do you use?
What differences do you see between IFs in array testing and in clinical
ES?
What kind of IFs do you report, firstly from the laboratory to the
clinician, and secondly from the clinician to the patient?
What kind of policy regarding IFs would you like to create in the future?
What impact do international guidelines on reporting IFs have on your
own practice?
What difficulties do you experience in your practice regarding IFs or
SFs?
What are the great challenges in the evolution of IFs?
What is your current practice regarding a patient’s request to opt out of
IFs?
How do you consider the intentional search for SFs?
What is your practice when new information is available about an IF, for
example for recontacting patients?
Abbreviations used: CMG Centre for medical genetics, IF(s) Incidental
finding(s), SF(s) Secondary finding(s), ES Exome sequencing.
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exhaustively and reviewed by the multidisciplinary group
of authors until consensus was reached between all of
them. Finally, quotes were selected and, if originally in
Dutch or French, translated by MS and TM to illustrate
the results. This article adheres to the COREQ guidelines
for reporting qualitative research [27].
Results
All eight Belgian CMGs agreed to participate. Every focus
group was composed multi-disciplinarily and involved be-
tween 6 and 11 participants, with a total number of 68
participating professionals (Table 2).
Six themes emerged from the data analysis: (i) current
and general practice in clinical genetic testing, (ii) the
position of genetics in medicine and society, (iii) criteria
for reporting IFs, (iv) impact of IFs and SFs, (v) policy
guidelines for genetic practice, (vi) guiding values and
principles. This article addresses the third theme of the
reporting criteria for IFs in a context of clinical ES in
adults.
When considering the reporting of IFs, Belgian CMGs
referred to two major criteria: the clinical significance of
the IF and patient-related factors.
Clinical significance of the IF
Currently, Belgian CMGs do not analyse the full exome
in clinical ES and mainly use exome-based panels, hith-
erto resulting in a rather limited experience with IFs in
clinical ES. However, whole exome sequencing (WES)
was identified as the undeniable future of clinical genet-
ics. Due to the many monogenic conditions, IFs are
expected to be frequent when very large panels or even
the full exome will be analysed.
Professionals also referred to the possibility of screen-
ing additional genes as SFs when sequencing the exome,
but a lack of (human, financial, and technical) resources
and an unfulfilled need for guidelines (for example re-
garding reimbursement and the scope of analysis) fail to
guarantee the required depth and trustworthiness of
additional analyses in clinical WES. This could result in
unnecessary interventions or harm and a false sense of
security. Therefore, Belgian CMGs do not deliberately
pursue SFs and only consider diagnostically unrelated
findings in clinical ES when they are unintentionally
identified as IFs (Table 3, Quote 1, Quote 2).
According to professionals in Belgian CMGs, reported
IFs should be clinically significant, i.e. they should be
relevant to a patient’s health. CMGs especially referred
to pathogenicity and medical actionability as important
components of an IF’s clinical significance. However,
throughout the focus groups, the exact delineation of
these criteria and their application in practice has turned
out to be challenging.
Pathogenicity
A reported IF has to be a clinical risk factor, i.e. a variant
predicted to cause disease, and various CMGs apply and
advocated a cut-off for pathogenicity in reportable IFs.
They suggested only reporting class 5 (pathogenic) and
class 4 (likely pathogenic) variants in diagnostically unre-
lated but known disease genes. Class 3 variants (variants
of uncertain significance or VUS), for example in an
unrelated breast cancer gene, are not reported, as this
might have a significant psychological impact or, as a
consequence of unnecessary interventions, medically
harmful consequences (Quote 3).
However, several factors complicate the definition of
clearly pathogenic IFs. Firstly, verifying IFs’ pathogenicity
and predictive value in any particular patient is challen-
ging in general, as there is usually no corresponding
phenotype (i.e. patients are non-symptomatic for the IF’s
associated disease). Secondly, professionals described
how, in the future, the advice not to report VUS in IFs
might not always be realised. When a VUS is identified,
it can be difficult to determine whether the affected gene
is related to the symptomatic condition or not. CMGs
noted that a VUS in a diagnostically relevant gene is
sometimes reported, but when the gene’s diagnostic rele-
vance is not fully guaranteed, this reporting might
undermine the cut-off for pathogenicity in IFs. Thirdly,
variant classifications are dynamic and a VUS may be
reclassified as a pathogenic variant over time. When this
variant turns out to be relevant to the symptomatic condi-
tion, its reclassification may eventually lead to a diagnosis,
which patients usually experience as a relief. Therefore,
professionals acknowledged the duty to recontact patients
Table 2 Focus group participants
FG1 FG2 FG3 FG4 FG5 FG6 FG7 FG8 Total
Participant’s profession
Clinical geneticist 3 3 4 5 3 3 2 2 25
Clinical laboratory geneticist 3 3 4 2 4 2 2 6 26
Genetic counsellor/Psychologist 4 1 2 1 1 2 11
Other (Bio-informatician, Bioethicist, Trainee MD) 1 1 3 1 6
Total 6 11 9 10 8 6 9 9 68
Abbreviations used: FG Focus group.
Saelaert et al. BMC Medical Genomics          (2019) 12:123 Page 4 of 11
regarding the reinterpretation of diagnostic results. In the
context of IFs, however, recontacting patients regarding a
reclassified VUS, was regarded as logistically impossible.
Moreover, professionals suggested that such a delayed
report of an IF would only be appropriate if patients expli-
citly agreed to it, as this finding is not directly related to
the indication for testing and does not realise the pursued
diagnosis.
Medical actionability
Most CMGs exclusively report actionable IFs, which were
described as findings for which medical therapy, treatment
or preventive screening are available (Quote 4). Several
professionals regarded the knowledge of IFs ad infinitum,
including non-actionable IFs, as harmful, because this
includes information that patients do not understand and
cannot handle (practically or psychologically). Profes-
sionals also expressed feeling powerless themselves about
non-actionable IFs and feeling “more comfortable with a
cancer predisposition than with [a predisposition for] a
neuro-degenerative condition”. These professionals con-
sidered the limitation of reportable IFs to actionable
results as a consequence of their professional duty and re-
sponsibility to decide on relevant information. Ultimately,
only reporting actionable IFs was presented as a pragmatic
way of keeping clinical ES practically feasible, as excluding
non-actionable findings reduces the time required for
analysis.
Even though they had not actually been in this situation,
some professionals remarked that not reporting non-ac-
tionable IFs, for example regarding a neuro-degenerative
condition, could be an ethically difficult decision, as it
would withhold important information from patients and/
or their families. Therefore, one CMG explicitly stated that
if they identified serious, non-actionable IFs, these would
be reported. Another CMG suggested that non-actionable
results might, depending on the specific circumstances, be
reported as IFs, but, if a practice for SFs were developed,
these deliberately pursued results should only concern
medically actionable findings.
Table 3 Quotes
Number Quote Participant
Quote 1 “Maybe, at random, we could find something and when we find something that we are sure of, we will
tell you. [… ] But we won’t actively look for it.”
FG 8 - P9 Clinical laboratory
geneticist
Quote 2 “There is a filter in accordance with the ACMG recommendations, but it is not used as standard. [ … ] It
takes considerable human capacity to analyse those things and currently it is not included in our
routine-protocol, to look at those things as standard.”
FG 7 - P7 Clinical laboratory
geneticist
Quote 3 “The reporting of variants where even we don’t know whether they mean anything, is the equivalent to
reporting non-information which might make a patient despair or ask for an impossible follow-up. [… ]
So I think we have a responsibility as professionals not to go that far.”
FG 2 - P10 Clinical laboratory
geneticist
Quote 4 A: “The example would be, in theory, because now we wouldn’t see it, eh, Huntington’s disease, if you
see that, at whatever age, should you transmit [report] it? So far, the answer is no. [… ] And any other
change for which you have nothing to offer to the patient, we don’t report.” […]
B: “But you can have Parkinson’s, Alzheimer’s … with a point mutation, for example.”
A:
FG 1 A = P5, Clinical geneticist
B = P1, Clinical geneticist
Quote 5 “[… ] and then, during the next pregnancy, they would find out that their child has Duchenne … You
don’t want to have this [kind of situation], whereas we have seen it during a previous [test], for example
in their daughter. So currently, we don’t work with an opt-out, to avoid this kind of thing. And I’ve never
met a family who had problems with this [practice].”
FG 2 - P2 Clinical geneticist
Quote 6 “[… ] so people have to decide between opt-in and opt-out, and I think it is very complex for people to
be sufficiently informed about this choice. [… ] It’s hopeless, people can’t choose, well, most of them
can’t. I mean, most people don’t have any background knowledge of genetics, so it is extremely difficult.”
FG 4 - P7 Psychologist
Quote 7 “A possibility to choose … You cannot simply force someone, I mean, you can’t just … The aim of
informed consent is to make a deliberate choice, so you have to give people the right information, so
they can make a choice. I think that is the aim of informed consent.”
FG 6 - P1 Genetic counsellor
Quote 8 A: “But, perhaps I don’t understand, if the patient chooses [an] opt-out, then we don’t report. [… ] If the
patient chooses, and it’s clear, to opt out, then we don’t report.”
FG 3 A = P1, Clinical geneticist
B: “But I would anyway! [… ] I would say, the consequence of not reporting and maybe losing a parent,
for example the [patient’s] mother very, very young … Those consequences are so important that I
would choose to disregard the patient’s decision, I would note it down in the file that I choose to
disregard, because [… ] I consider the consequence of not reporting to be worse than the consequences
of reporting.”
B = P8, Clinical geneticist
Quote 9 “So generally, when we have an IF like that, most of the time there is a deliberation between the
biologist [clinical laboratory geneticist] who is responsible for the analysis and the clinician [clinical
geneticist] who validates the test. [… ] Sometimes, we even call upon external people, other centres, or
people who have the right experience.”
FG 5 - P5 Clinical geneticist
Abbreviations used: FG Focus group, P Participant, IF(s) Incidental finding(s), ACMG American College of Medical Genetics and Genomics
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The use of a standard list of medically actionable genes
was proposed. Many Belgian CMGs use the ACMG list of
“highly penetrant and actionable genes” as a (not strictly
binding) framework for reportable IFs [2, 3]. On the other
hand, some CMGs considered such a list as being in con-
flict with the dynamic reality of treatments and preventions
that can become available over time. Hence a variant’s
actionability might better be determined at the time of
discovery.
Finally, a correlation was suggested between a condi-
tion’s actionability and penetrance. Even though risks
are subjectively interpreted, “low penetrance” IFs were
considered to be too abstract, and classifying them as ac-
tionable might create unrealistic expectations regarding
the utility of this information. Therefore, as a suggestion
for future policy, actionable IFs should be highly pene-
trant and patients should be counselled in interpreting
incomplete penetrance.
Patient-related factors
As a second criterion for reporting IFs, CMGs referred
to patient-related factors, being the patient’s preference
to know IFs and patient characteristics.
Preference to know
ES allows a selection of analysed genes and hence, theor-
etically, a choice to receive IFs or not. However, not all
Belgian CMGs offer this opportunity, and practices on a
patient opt-in and opt-out vary widely.
Three CMGs currently offer no opt-out of actionable
IFs, although one of them offers an opt-out of non-ac-
tionable IFs. Professionals at these CMGs argued firstly
that they have the ambition or even the duty to prevent
future disease that can be avoided (Quote 5) and sec-
ondly that lay people do not truly understand the mean-
ing and possible impact of IFs. In the event of an opt-
out, patients would not realise what they are actually de-
clining (Quote 6). As a third argument, two CMGs men-
tioned their ethics committee’s influence on this policy.
It did not allow an opt-out of actionable IFs because
professionals should report useful information when it is
available and, again, because patients would not under-
stand their own decision. Finally, it was observed that
patients generally do not dispute the possibility of re-
ceiving actionable IFs. One CMG added that, even if an
opt-out is not suggested, patients can spontaneously ask
for it, but no such cases were mentioned during the
focus group.
Despite these arguments, one CMG explicitly discussed
its current policy and reported an exception by honouring
a patient’s request not to look at breast cancer genes dur-
ing an unrelated clinical ES. Two centres mentioned that
it would be good to update their ethics committee on re-
cent developments in clinical ES, possibly to re-evaluate
their opt-out policy. Finally, it was recognised that patients
might be distressed when discovering future health risks
as IFs. Nonetheless, these worries were said to be inevit-
able, as the risk would probably manifest itself anyway at a
later point in life.
Conversely, four CMGs always allow an opt-out of
actionable IFs. To justify their policy, these CMGs also
referred to the idea that IFs might be complex to compre-
hend, also in psychological terms. Some patients might
not be able to deal with the information, and therefore
their preference to opt out of these results should be
respected. Moreover, these CMGs stated that patients’
general and fundamental right not to know should be
honoured (Quote 7). Nevertheless, it was mentioned that
only a small minority of patients actually choose to opt
out of actionable IFs.
Finally, one CMG, with limited experience with clinical
ES, discussed its future policy and the possibility of an
opt-out in depth. While some of its professionals strongly
defended absolute respect for a patient’s choice, one par-
ticipant claimed that opting out should only be accepted if
it has minor implications for the patient’s prognosis.
When not reporting actionable IFs could have severe
consequences, this professional would overrule a patient’s
opt-out. Again it was argued that patients do not under-
stand what IFs and an opt-out really mean. Moreover, the
possible harm of not reporting an actionable IF would
outweigh the harm of being informed against one’s will
(Quote 8). To reconcile the two perspectives in this CMG,
two opposing solutions were suggested for a patient’s opt-
out: the IF could be reported at a later and more suitable
moment, or the IF could be masked in the report from the
laboratory to the clinician. That way, situations where the
clinician knows but cannot disclose relevant patient infor-
mation could be avoided.
Patient characteristics
Finally, professionals noted that patient characteristics
influence whether and how an IF is reported, as patients'
(clinical and personal) context interacts with the IF’s
clinical significance and affects its final relevance. Profes-
sionals provided the hypothetical example of the import-
ance of a patient’s primary condition for the timing of
reporting an IF as well as for the suggested follow-up
and counselling, since both results are considered to
have an integrated impact on a patient’s health and life.
A patient’s wish for future children or his/her family his-
tory of illness might also affect the disclosure of an IF
regarding a carrier status or of a non-actionable IF (since
it could explain an undiagnosed family condition). These
last examples illustrated how personal and family char-
acteristics interact with the definition of actionability
and hence might affect an IF’s clinical significance and
disclosure. Most CMGs did not consider actionability to
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include lifestyle adjustments or personally useful actions.
However, they did discuss actionability in terms of
reproductive decision making, which would enable the
reporting of IFs concerning a carrier status for a reces-
sive condition. Some professionals do or would not
report these findings, because they are not clinically
threatening for patients themselves. It was also men-
tioned that including prenatal possibilities “would make
every condition actionable”. However, and depending on
personal and/or family characteristics and plans, these
results can be relevant to relatives and (future) children.
Therefore, half of the CMGs would consider the report-
ing of IFs regarding a carrier status for severe diseases
(for example cystic fibrosis or Duchenne muscular
dystrophy). Two centres already reported such findings
and one does not offer an opt-out of them. Nonetheless,
the psychological impact of this disclosure was
acknowledged and one CMG testified about a family
that was emotionally upset by the disclosure of a cystic
fibrosis carrier status.
The interaction between, on the one hand, a patient’s
characteristics and (clinical, personal, reproductive, fam-
ily, etc.) context and, on the other hand, the clinical
significance (including the actionability) of IFs does not
result in a standard outcome, and hence evaluating an
IF’s final relevance frequently requires a professional,
multidisciplinary deliberation (Quote 9). To facilitate the
deliberation process, a national (online) consortium on
IFs was suggested, where “difficult cases” could be dis-
cussed, as well as a specialist committee to relieve CMGs
of the exclusive responsibility regarding disclosure.
Despite the case-by-case deliberation, some profes-
sionals would still prefer general guidelines, for example
regarding pathogenic variants and actionability, to facili-
tate the professional decision about disclosure.
Discussion
An analysis of current practice at Belgian CMGs regard-
ing clinical ES in the context of adult testing revealed a
diagnostic focus and a standard procedure of exome-
based panel testing, resulting in a low incidence of IFs.
Belgian CMGs’ collective policy not to deliberately pur-
sue SFs mirrors the avoidance of diagnostically unrelated
findings and accords with current laboratory practices
and with all international guidelines apart from the
ACMG recommendations [1–3, 6–8, 23, 28].
Whether CMGs report an IF is determined by an
interaction between the clinical significance of the IF
and patient-related factors.
Clinical significance of the IF
Belgian professionals indicated pathogenicity and med-
ical actionability as important components of an IF’s
clinical significance. These criteria are not surprising in
themselves, as they are also stressed by leading American
and European recommendations [1–3, 7]. Nonetheless,
these criteria were extensively discussed because their
interpretation and application in practice turns out to be
challenging.
The importance of IFs’ pathogenicity was unanimously
emphasised. However, Belgian CMGs also expressed
concerns about IFs’ disease predictive value in asymp-
tomatic persons. This idea is echoed internationally,
even by the ACMG itself [3, 6, 9, 29, 30]. Richards et al.
mentioned that variants might be less pathogenic and
less penetrant if they are unrelated to the primary test
indication and when there is no phenotype or family his-
tory of the associated condition [12]. The caution with
which Belgian professionals approach the pathogenicity
of IFs reflects these remarks, as well as the warning that
unreliably interpreted and reported results might cause
physical and psychological harm [15, 31]. The parallel
idea expressed by Belgian CMGs regarding a cut-off for
pathogenicity in IFs, and the suggestion to only report
class 5 and class 4 but not class 3 variants (VUS),
accords with international laboratory practices and
points to consider, and with the ACMG recommenda-
tions [2–4, 6, 21]. Not reporting VUS in IFs from the
laboratory to the ordering clinician prevents an over-inter-
pretation of these results’ significance for the diagnostic
question and needless patient follow-up [6, 23, 32].
Along with pathogenicity, most but not all CMGs assessed
an additional threshold for reportable IFs, being their action-
ability. This criterion, as well as its interpretation as medical
actionability, corresponds with an international consensus
and might be partly explained by professionals’ specific role
as medical experts [1, 3, 5, 11, 28–30, 33]. Nonetheless, the
exclusive reporting of actionable IFs was characterised
as a dynamic and ethically difficult policy by some
Belgian centres. Some CMGs suggested to identify low
penetrance IFs as non-actionable, which refers to a cor-
relation between criteria that has already been indicated
by the ACMG and its current list of 59 “highly pene-
trant and actionable genes” that should be analysed as
SFs [2, 3]. Conversely, it has also been suggested that
variants’ low penetrance can be countered by the asso-
ciated condition’s actionability [28, 30].
Patient-related factors
A notable finding of this study is Belgium’s diverse prac-
tice regarding the opt-out of actionable IFs. The absence
of the possibility to opt out was legitimised by the profes-
sional aim to avoid harm. However, in-house discussions
about this mandatory opt-in policy and professional
concerns about the psychological impact of reported IFs
illustrated that the superiority of professional duty over a
patient’s choice is not self-evident. This value conflict was
most visible in one CMG’s consideration of overruling a
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patient’s choice to opt out when it was considered to have
harmful consequences. The denial of a patient’s prefer-
ence, granting this criterion only a relative weight, sounds
polemical but is in line with the “prudent professional
judgement” which is advocated by bodies including the
ESHG and Bioethics Commission [1, 5]. It also reflects the
idea that the denial of a patient’s choice is sometimes in-
evitable, for example when a patient opts out of clinically
relevant or medically actionable IFs [9, 16, 31]. The sec-
ond argument for the obligatory disclosure of actionable
IFs, being patients’ presumed inability to fully understand
their impact, has also been suggested internationally [9, 32].
However, postulating a patient’s inability to make well-in-
formed decisions might discount the efficacy of counselling
procedures [5, 8, 34].
Patients’ general acceptance of disclosing actionable
IFs supports the consolidation of offering no opt-out.
However, an absence of questions might not necessarily
equal an omnipresent preference to actually know IFs.
When a CMG does not suggest an opt-out, few patients
might have the genetic literacy to ask for one spontan-
eously, since the public understanding of genetics and
its possibilities seems to be rather limited [35]. More-
over, it takes courage to dispute the professional author-
ity of an informed consent form or pre-test counselling,
or to resist the societal pressure to know as much as
possible [33, 36]. Finally, a Belgian CMG’s claim that an
IF, and the corresponding psychological distress, will
manifest itself anyway at a later time might not be com-
pletely valid, as the incidentally identified variant could
have an incomplete penetrance and/or variable expres-
sion, an idea related to the uncertain pathogenicity of
IFs in asymptomatic persons.
Belgian CMGs that allow an opt-out of actionable IFs
emphasise the honouring of patients’ wishes and their
right not to know. This conflicts with well-known
European recommendations but accords with a Canadian
position statement and recent points to consider, and it
is supported by international professional preferences
[6, 8, 30, 37]. The Belgian suggestion that results should
be masked in the laboratory report for the clinician
when patients opt out, has been expressed internation-
ally [31]. However, problems might arise when, as a
result of changed circumstances or values, patients
change their mind and do want to know IFs [16].
Finally, there is a general agreement, both within Belgian
CMGs and internationally, that the interaction between
an IF’s clinical significance and patient characteristics af-
fects the final relevance of an IF [9, 15, 16, 23, 30, 32, 33].
This interaction clearly shows in the impact of a patient’s
personal context on the criterion and definition of IFs'
actionability and, more particularly, in the relevance
and possible disclosure of IFs regarding a carrier status.
Both within Belgian CMGs and internationally, this
possible reporting is strongly discussed, as it might
enable reproductive and/or (future) family-wide choices
and actions [9, 23, 30, 33]. Even though reporting a car-
rier status for recessive conditions is in conflict with
Belgian CMGs’ general focus on direct, medical action-
ability, half of them would favour such reporting to
adults. This disclosure is supported by international
professionals’ preferences and recent laboratory points
to consider [6, 16, 21, 23]. On the other hand, it con-
flicts with the ACMG recommendations and creates an
additional workload for results which are not clinically
significant for patients themselves [2, 3, 16, 23]. How-
ever, this claim of reduced significance is countered by
the impact of a reported carrier status on a person’s self-
concept and specifically by the way it might threaten a
person’s genetic identity, (future) health perception or
wished-for parental role [38, 39], a psychological effect
which was also insinuated by two Belgian CMGs. The im-
pact of knowing one’s carrier status might even be more
substantial in the case of a serious X-linked condition,
such as fragile X syndrome, where carrying the premuta-
tion might also have clinical consequences for the carrier
herself [40]. Belgian professionals did not raise this specific
example of an IF regarding a carrier status, but nonethe-
less it goes against their statement that such a finding is
non-threatening for patients themselves.
The reporting of IFs regarding a carrier status because
of its possible value in the specific (personal or family)
context of reproduction, can be considered in the more
general debate on personal utility [19]. The concept of
personal utility might, based on a patient’s characteris-
tics and context, categorise findings which allow future
(reproductive) choices, psychological or social coping or
intrinsically valuable self-knowledge as reportable re-
sults, as they enable non-medical but valuable actions
[19, 41]. Even though CMGs acknowledge the import-
ance of a patient’s context and the difficulty of not
reporting medically non-actionable IFs, most CMGs are
not likely to add these options of personal utility to the
actionability-criterion. Moreover, personal utility risks
becoming an unspecified umbrella term that justifies the
reporting of any kind of results [19, 42]. Therefore,
Bunnik et al. suggest limiting personal utility to mean-
ingful, technically and clinically valid information which
“can reasonably be used for decisions, actions or self-un-
derstanding” [42]. As a consequence of its problematic
definition, Vears et al. even suggest not assessing action-
ability as a decisive criterion for reporting pathogenically
significant IFs [6].
As a second consequence of the interaction between
an IF’s clinical significance and patient characteristics,
the value of professional deliberation is stressed by both
Belgian and international professionals [9, 11, 16, 23].
On the other hand, some CMGs’ call for guidelines on
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pathogenicity or actionability is also mirrored in inter-
national research, for example, concerning clinical labora-
tory geneticists who favour a list of conditions and genes
that should be considered [9, 11, 15, 23, 29].
The tension between a call for (more) guidelines and a
patient-specific, case-by-case deliberation has been iden-
tified previously [23]. As ES is increasingly implemented
in clinical practice, it seems advisable, at least at a local
level of CMGs, to create a guiding framework which is
clarified to patients before testing and which relieves
professionals from the responsibility to individually
decide on every case of IFs. To further avoid the chance
and injustice of offering different information to differ-
ent patients, not only within but also between CMGs,
an (inter)national consensus on relevant criteria might
be pursued as a starting point for reporting practices
[20, 22, 23, 43]. However, if general guidelines turn out
to be unfeasible and the current diversity in national
practice, as disclosed by this study, and in international
practice and policy documents is maintained, a patient’s
informed decision on which results to receive, starts
with his/her choice of a specific CMG. In that case, it is
quintessential for every CMG to disclose its local pol-
icy. On the other hand, and in line with the non-stan-
dardised outcome of the interaction between the
clinical significance of IFs and patient characteristics, a
flexibility in guidelines’ application has been advocated
so they can be accustomed to the particular context
[44]. Together with the professional expertise in CMGs,
this call for a personalised deliberation nuances the
need for and effectiveness of a rigid “one model fits all”
policy [23]. Therefore, the contextualised application of
a guiding framework of reporting criteria for IFs, might
result in a personalised, non-standardised outcome.
To our knowledge, this is the first study on reporting
practices and criteria regarding IFs which includes na-
tionwide certified CMGs and hence achieves a good
coverage of a national, non-commercial practice. The
organization of one focus group in every centre revealed
the similarities and differences in practice between cen-
tres. Moreover, it encouraged an open discussion between
colleagues and a clarification of underlying reporting cri-
teria. These results emerged from a Belgian context, with
its specific scale and healthcare organisation. Nonetheless,
the results of this study might be (partly) transferrable to
other (and larger) countries with similar healthcare
systems and analogous confrontations with diverse inter-
national guidelines, but further research is needed to
confirm or deny similarities in practice and policy. As a
consequence of Belgian CMGs’ standard practice of diag-
nostic exome-based panel testing, there is still a limited
experience with actual IFs in clinical ES. Consequently,
the perspectives expressed by the CMGs might reflect
current reporting practices as well as preferable future
policies. Future research should identify whether these
perspectives are actually effected when the exome is fully
analysed in clinical practice and IFs become more
frequent.
Conclusions
Belgian CMGs agree in their reference to common and
internationally suggested reporting criteria for IFs. How-
ever, these criteria resist a uniform interpretation and hence
result in a diversified Belgian practice, which reflects diver-
gent, international policy perspectives. Belgian CMGs con-
sent to the threshold of pathogenicity but concerns about
IFs’ predictive value in non-symptomatic persons and VUS
in IFs challenge this criterion’s application in practice. Fur-
thermore, (medical) actionability is both an advocated and
contested threshold, both internationally and at Belgian
CMGs. In their adherence to international perspectives,
Belgian CMGs differ most manifestly regarding patient opt-
out possibilities for actionable IFs and in the weighing of
professional duty versus patient autonomy. Finally, the
interaction between the clinical significance of IFs and
patient characteristics questions the definition of actionabil-
ity and the possible reporting of IFs with personal utility
such as findings concerning a carrier status. The import-
ance of the patient’s context and the non-standardised
outcome of its interaction with IFs’ clinical significance
suggest the imminent inclusion of case-by-case reflections
in reporting decisions. Accordingly, (international) guide-
lines for the reporting of IFs in clinical ES might only be
effective when they are sufficiently detailed in terms of the
criteria applied as well as responsive to the particularity of
each individual case.
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